Alector, Inc. (ALEC) vs Protalix BioTherapeutics, Inc. (PLX)

Alector, Inc. and Protalix BioTherapeutics, Inc. are both Biotechnology companies. Alector, Inc. and Protalix BioTherapeutics, Inc. are of similar size ($221.6M and $214.4M). Alector, Inc. has negative trailing earnings, so its P/E is not meaningful; Protalix BioTherapeutics, Inc. trades at 11.3×. Protalix BioTherapeutics, Inc. grew revenue faster over the last twelve months: 30.1% against −82.9%. Protalix BioTherapeutics, Inc. has the higher net margin (23.5% vs −850.1%) and the higher return on invested capital (48.5% vs 0.00%). Across the 17 metrics below, Protalix BioTherapeutics, Inc. leads on 11 and Alector, Inc. on 6.

Valuation

Metric ALEC PLX Biotechnology median
P/E n/m 11.33 7.88
P/S 15.65 2.70 11.47
P/B n/m 3.05 2.52
Price to free cash flow n/m 28.37 21.16
EV/EBITDA n/m 7.27 0.74
EV/Sales 4.49 2.24 10.73
Earnings yield (56.41%) 8.82% (28.84%)
Free cash flow yield (73.03%) 3.52% (23.03%)

Profitability

Metric ALEC PLX Biotechnology median
Gross margin 100.00% 69.20% 65.16%
Operating margin (912.40%) 28.89% 0.00%
Net margin (850.13%) 23.50% 0.00%
Free cash flow margin (1,142.55%) 9.51% 0.00%
Return on equity (385.11%) 31.23% (57.72%)
Return on assets (42.15%) 20.07% (49.22%)
Return on invested capital 0.00% 48.48% 0.00%

Growth

Metric ALEC PLX Biotechnology median
Revenue growth (TTM) (82.91%) 30.14% 5.64%
EPS growth (last fiscal year) (13.01%) (300.00%) —
Revenue growth, 5-year CAGR (0.05%) (3.46%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALEC PLX Biotechnology median
Debt to equity (0.99) 0.00 0.00
Current ratio 5.26 2.94 4.73
Net debt to EBITDA 1.61 7.68 0.96

Dividend

Metric ALEC PLX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ALEC PLX Biotechnology median
Market cap 214.38m 221.57m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack